US Stock MarketDetailed Quotes

LGVN Longeveron

Watchlist
  • 1.650
  • -0.100-5.71%
Close Apr 28 16:00 ET
  • 1.630
  • -0.020-1.21%
Pre 09:02 ET
24.68MMarket Cap-0.63P/E (TTM)

About Longeveron Company

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Company Profile

SymbolLGVN
Company NameLongeveron
Listing DateFeb 12, 2021
Issue Price10.00
Founded2014
CEOMr. Mohamed Wael Ahmed Hashad
MarketNASDAQ
Employees26
Fiscal Year Ends12-31
AddressLife Science & Technology Park,1951 NW 7th Avenue,Suite 250
CityMiami
ProvinceFlorida
CountryUnited States of America
Zip Code33136
Phone1-844-470-2550
Websitehttp://www.longeveron.com

Company Executives

  • Name
  • Position
  • Salary
  • Mohamed Wael Ahmed Hashad
  • Chief Executive Officer and Director
  • 1.85M
  • Lisa Locklear
  • Treasurer, Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • 1.12M
  • Devin Blass
  • Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls
  • --
  • Dr. Nataliya Agafonova
  • Chief Medical Officer
  • --
  • Dr. Joshua M. Hare, M.D.
  • Chief Science Officer and Chairman of the Board
  • 640.39K
  • Lisa McClain-Moss
  • Vice President, Manufacturing
  • --
  • Rock Soffer
  • Director
  • 101.56K
  • Ursula Ungaro
  • Independent Director
  • 113.81K
  • Neha Motwani
  • Independent Director
  • 56.13K
  • Richard N. Kender, M.B.A.
  • Independent Director
  • 60.23K
  • Khoso Baluch
  • Independent Director
  • 120.31K
  • Dr. Roger Hajjar
  • Independent Director
  • 56.26K
  • Paul Lehr
  • General Counsel and Secretary
  • 1.23M

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Oracle
ORCL
140.140
Vale SA
VALE
9.600
Toll Brothers
TOL
101.120
4
D.R. Horton
DHI
125.170
5
Lennar Corp
LEN
108.150
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Discussing

Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀